{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:16:35Z","timestamp":1783041395021,"version":"3.54.6"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003411","name":"Gangneung Asan Hospital","doi-asserted-by":"publisher","award":["2020-IB008"],"award-info":[{"award-number":["2020-IB008"]}],"id":[{"id":"10.13039\/501100003411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Bacillus Calmette\u2013Gu\u00e9rin (BCG) is the gold standard adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). However, given the current global shortage of BCG, new treatments are needed. We evaluated tumor microenvironment markers as potential BCG alternatives for NMIBC treatment. Programmed death-ligand 1, human epidermal growth factor receptor-2 (HER2), programmed cell death-1 (PD1), CD8, and Ki67 levels were measured in treatment-na\u00efve NMIBC and MIBC patients (pTa, pT1, and pT2 stages). Univariate and multivariate Cox proportional hazard models were used to determine the impact of these markers and other clinicopathological factors on survival, recurrence, and progression. EP263, IM142, PD1, and Ki67 levels were the highest in the T2 stage, followed by the T1 and Ta stages. HER2 and IM263 expressions were higher in the T1 and T2 stages than in the Ta stage. In NMIBC, the significant prognostic factors for recurrence-free survival were adjuvant therapy, tumor grade, and HER2 positivity, whereas those for progression-free survival included age, T-stage, and IM263. Age, T-stage, EP263, PD1, CD8, and Ki67 levels were significant factors associated with overall survival. IM263 and HER2 are potential biomarkers for progression and recurrence, respectively. Therefore, we propose HER2 as a potential target antigen for intravesical therapeutics as a BCG alternative.<\/jats:p>","DOI":"10.3389\/fimmu.2022.903297","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T04:36:06Z","timestamp":1653280566000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Identification of New Prognostic Markers and Therapeutic Targets for Non-Muscle Invasive Bladder Cancer: HER2 as a Potential Target Antigen"],"prefix":"10.3389","volume":"13","author":[{"given":"Han Kyu","family":"Chae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wook","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Gwun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong-Joo","family":"Noh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil Hyun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Yeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae-Woon","family":"Eom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on non-Muscle-Invasive Bladder Cancer (TaT1 and Carcinoma in Situ) \u20132019 Update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3-Month Clinical Response to Intravesical Therapy as a Predictive Factor for Progression in Patients With High Risk Superficial Bladder Cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000062605.92268.c6","article-title":"Defining Bacillus Calmette-Guerin Refractory Superficial Bladder Tumors","volume":"169","author":"Herr","year":"2003","journal-title":"J Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)32741-6","article-title":"Durability of the Tumor-Free Response for Intravesical Bacillus Calmette-Guerin Therapy","volume":"152","author":"Nadler","year":"1994","journal-title":"J Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12012","article-title":"Current Clinical Practice Gaps in the Treatment of Intermediate- and High-Risk non-Muscle-Invasive Bladder Cancer (NMIBC) With Emphasis on the Use of Bacillus Calmette\u2013Gu\u00e9rin (BCG): Results of an International Individual Patient Data Survey (IPDS)","volume":"112","author":"Witjes","year":"2013","journal-title":"BJU Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.04.066","article-title":"Treatment of High-Grade non-Muscle-Invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial \u201cNimbus\u201d","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced and Unresectable or Metastatic Urothelial Cancer (KEYNOTE-052): A Multicentre, Single-Arm, Phase 2 Study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as First-Line Treatment in Cisplatin-Ineligible Patients With Locally Advanced and Metastatic Urothelial Carcinoma: A Single-Arm, Multicentre, Phase 2 Trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab Monotherapy for the Treatment of High-Risk non-Muscle-Invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-Label, Single-Arm, Multicentre, Phase 2 Study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000000789","article-title":"Bladder Sparing Landscape for Bacillus Calmette\u2013Gu\u00e9rin Unresponsive Bladder Cancer","volume":"30","author":"Soria","year":"2020","journal-title":"Curr Opin Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.0994","article-title":"Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2\/Neu-Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial","volume":"25","author":"Hussain","year":"2007","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-Label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients With Locally Advanced or Metastatic Urothelial Carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.07.020","article-title":"A Phase II Study of Oportuzumab Monatox: An Immunotoxin Therapy for Patients With Noninvasive Urothelial Carcinoma in Situ Previously Treated With Bacillus Calmette\u2013Gu\u00e9rin","volume":"188","author":"Kowalski","year":"2012","journal-title":"J Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting Recurrence and Progression in Individual Patients With Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients From Seven EORTC Trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s00292-018-0507-x","article-title":"Predictive Value of PD-L1 Diagnostics","volume":"39","author":"Schildhaus","year":"2018","journal-title":"Pathologe"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.11.007","article-title":"Multi-Institutional Validation of the Predictive Value of Ki-67 in Patients With High Grade Urothelial Carcinoma of the Upper Urinary Tract","volume":"193","author":"Krabbe","year":"2015","journal-title":"J Urol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-Driven Biomarkers to Guide Immune Checkpoint Blockade in Cancer Therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) Expression by Urothelial Carcinoma of the Bladder and BCG-Induced Granulomata: Associations With Localized Stage Progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1134412","article-title":"The Ratio of CD8 to Treg Tumor-Infiltrating Lymphocytes is Associated With Response to Cisplatin-Based Neoadjuvant Chemotherapy in Patients With Muscle Invasive Urothelial Carcinoma of the Bladder","volume":"5","author":"Baras","year":"2016","journal-title":"Oncoimmunology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.679928","article-title":"PD-1-Positive Tumor-Associated Macrophages Define Poor Clinical Outcomes in Patients With Muscle Invasive Bladder Cancer Through Potential CD68\/PD-1 Complex Interactions","volume":"11","author":"Jiang","year":"2021","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102794","article-title":"Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 non-Muscle Invasive Bladder Cancer and Their Association With Prognosis","volume":"12","author":"Kubon","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.615091","article-title":"Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer","volume":"11","author":"Lim","year":"2020","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"11702","DOI":"10.1038\/s41598-017-11291-0","article-title":"Comprehensive Multiregional Analysis of Molecular Heterogeneity in Bladder Cancer","volume":"7","author":"Thomsen","year":"2017","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.humpath.2019.04.003","article-title":"Tumor Immune Microenvironment in non-Muscle-Invasive Urothelial Carcinoma of the Bladder","volume":"89","author":"Eich","year":"2019","journal-title":"Hum Pathol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1920","article-title":"Adaptive Immune Resistance to Intravesical BCG in non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials","volume":"26","author":"Kates","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.11.007","article-title":"Performance of the Food and Drug Administration\/EMA-Approved Programmed Cell Death Ligand-1 Assays in Urothelial Carcinoma With Emphasis on Therapy Stratification for First-Line Use of Atezolizumab and Pembrolizumab","volume":"106","author":"Eckstein","year":"2019","journal-title":"Eur J Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00428-019-02610-z","article-title":"Multicentric Analytical Comparability Study of Programmed Death-Ligand 1 Expression on Tumor-Infiltrating Immune Cells and Tumor Cells in Urothelial Bladder Cancer Using Four Clinically Developed Immunohistochemistry Assays","volume":"475","author":"Schwamborn","year":"2019","journal-title":"Virchows Arch"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.11.002","article-title":"PD-L1 Antibody Comparison in Urothelial Carcinoma","volume":"75","author":"Rijnders","year":"2019","journal-title":"Eur Urol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40425-017-0299-1","article-title":"Biomarkers for Immunotherapy in Bladder Cancer: A Moving Target","volume":"5","author":"Aggen","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4333","article-title":"Mutational Landscape of Metastatic Cancer Revealed From Prospective Clinical Sequencing of 10,000 Patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-015-9552-6","article-title":"HER2 Expression Status in Diverse Cancers: Review of Results From 37,992 Patients","volume":"34","author":"Yan","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab After Adjuvant Chemotherapy in HER2-Positive Breast Cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in Combination With Chemotherapy Versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2012-200944","article-title":"Her2 Amplification Distinguishes a Subset of non-Muscle-Invasive Bladder Cancers With a High Risk of Progression","volume":"66","author":"Chen","year":"2013","journal-title":"J Clin Pathol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601245","article-title":"HER2\/neu Overexpression in the Development of Muscle-Invasive Transitional Cell Carcinoma of the Bladder","volume":"89","author":"Latif","year":"2003","journal-title":"Br J Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11477","article-title":"HER-2 and TOP2A Coamplification in Urinary Bladder Cancer","volume":"107","author":"Simon","year":"2003","journal-title":"Int J Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.eururo.2020.05.021","article-title":"Goldilocks and the BCG: Bacillus Calmette\u2013Gu\u00e9rin Dose Reduction in the Age of Shortage","volume":"78","author":"Nikas","year":"2020","journal-title":"Eur Urol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.09.018","article-title":"Diffusive Ki67 and Vimentin are Associated With Worse Recurrence-Free Survival of Upper Tract Urothelial Carcinoma: A Retrospective Cohort Study From Bench to Bedside","volume":"40","author":"Yang","year":"2022","journal-title":"Urol Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03202-0","article-title":"Selected Protein Expression in a New Prognostic Model for Patients With non-Muscle-Invasive Bladder Cancer","volume":"146","author":"Semeniuk-Wojta\u015b","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-019-00678-1","article-title":"Intensity of Nuclear Staining for Ki-67, P53 and Survivin as a New Prognostic Factor in non-Muscle Invasive Bladder Cancer","volume":"26","author":"Stec","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"300060519895847","DOI":"10.1177\/0300060519895847","article-title":"HER-2 Overexpression is a Negative Predictive Factor for Recurrence in Patients With non-Muscle-Invasive Bladder Cancer on Intravesical Therapy","volume":"48","author":"Moustakas","year":"2020","journal-title":"J Int Med Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2015.03.004","article-title":"Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma","volume":"1","author":"McDaniel","year":"2016","journal-title":"Eur Urol Focus"},{"key":"B47","article-title":"Her-2\/Neu Overexpression in Muscle-Invasive Urothelial Carcinoma of the Bladder: Prognostic Significance and Comparative Analysis in Primary and Metastatic Tumors","volume":"7","author":"Jimenez","year":"2001","journal-title":"Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2018.06.028","article-title":"PD-L1 Expression in Tumor Cells and the Immunologic Milieu of Bladder Carcinomas: A Pathologic Review of 165 Cases","volume":"81","author":"Davick","year":"2018","journal-title":"Hum Pathol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.903297\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T04:36:10Z","timestamp":1653280570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.903297\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2022.903297"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.903297","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]},"article-number":"903297"}}